Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Ost

Showing results (1-10 of 334) with videos related to

Pageof 34
Sort By:
European Urology|September 20, 2018
It Ain't Over Till the Fat Lady Sings: The POPSTAR TrialPiet Ost
Nature Reviews. Urology|December 11, 2019
PSMA PET-CT redefines nonmetastatic castration-resistant prostate cancerPiet Ost
European Urology Oncology|February 28, 2024
Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Piet Ost, Shankar Siva, Sugmund Brabrand, et al. PEACE V-Salvage Treatment of Oligorecurrent Nodal Prostate Cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007Thomas Zilli, Piet Ost
European Urology|May 28, 2019
Re: Assessment of <sup>68</sup>Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical TrialBoris Hadaschik, Piet Ost
International Journal of Radiation Oncology, Biology, Physics|September 26, 2024
PSMA PET-CT, When Seeing Becomes ImprovingPiet Ost, Nicolas Mottet
European Urology|March 2, 2016
Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30Piet Ost, Pirus Ghadjar
Oncotarget|October 23, 2018
Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?Thomas Zilli, Piet Ost
European Urology|September 4, 2018
Current Insights in the Management of High-risk Prostate Cancer: Still More Questions than AnswersValerie Fonteyne, Piet Ost
The Lancet. Oncology|July 31, 2025
Reflections on the PEACE V-STORM trial - Authors' replyPiet Ost, Thomas Zilli,
European Urology|November 19, 2018
Re: [<sup>177</sup>Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 StudyKathia De Man, Piet Ost
Pageof 34

Showing results (1-10 of 334) with videos related to

Sort By:
Pageof 34
European Urology|September 20, 2018
It Ain't Over Till the Fat Lady Sings: The POPSTAR TrialPiet Ost
Nature Reviews. Urology|December 11, 2019
PSMA PET-CT redefines nonmetastatic castration-resistant prostate cancerPiet Ost
European Urology Oncology|February 28, 2024
Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Piet Ost, Shankar Siva, Sugmund Brabrand, et al. PEACE V-Salvage Treatment of Oligorecurrent Nodal Prostate Cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007Thomas Zilli, Piet Ost
European Urology|May 28, 2019
Re: Assessment of <sup>68</sup>Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical TrialBoris Hadaschik, Piet Ost
International Journal of Radiation Oncology, Biology, Physics|September 26, 2024
PSMA PET-CT, When Seeing Becomes ImprovingPiet Ost, Nicolas Mottet
European Urology|March 2, 2016
Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30Piet Ost, Pirus Ghadjar
Oncotarget|October 23, 2018
Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?Thomas Zilli, Piet Ost
European Urology|September 4, 2018
Current Insights in the Management of High-risk Prostate Cancer: Still More Questions than AnswersValerie Fonteyne, Piet Ost
The Lancet. Oncology|July 31, 2025
Reflections on the PEACE V-STORM trial - Authors' replyPiet Ost, Thomas Zilli,
European Urology|November 19, 2018
Re: [<sup>177</sup>Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 StudyKathia De Man, Piet Ost
Pageof 34